Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Regeneron Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
Regeneron Announces Investor Conference Presentation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Reports Third Quarter 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AZN REGN
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NTLA REGN
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Provides Update on Planned Chief Financial Officer Transition
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Updates to Board of Directors
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.